Quince Advances Rare Disease Drug Trial with FDA Fast Track Status, $40M War Chest - Stock Titan
2025-03-24 • Google News
Quince Therapeutics, Inc. (QNCX)
US$ 1.38994.5%
Price Chart
Key Statistics
Market Cap
$ 84.99M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
101.17K
52W High
$ 2.45
52W Low
$ 0.51
Dividend Yield
0.00%
Beta
0.80
Technicals
50-Day MA
1.1919
200-Day MA
1.364
52 Week High
2.45
52 Week Low
0.5116
About QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Employees
36
Headquarters
South San Francisco, CA
CEO
Dr. Dirk Thye M.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg